The review found no eligible studies for this question.
The review found no eligible studies for this question.
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in AJBR compared with pegylated liposome FVIII formulation (low certainty).
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in ABR compared with pegylated liposome FVIII formulation (low certainty).
HAART + paclitaxel showed no clear difference in progression of Kaposi's sarcoma compared with HAART + pegylated liposomal doxorubicin (moderate certainty).
HAART + paclitaxel showed no clear difference in clinical response ‐ complete response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).
HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).
HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).
Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).
The review found no eligible studies for this question.
Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).
Summary of findings 3: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with PLD alone (moderate certainty).